Trial: 202012109

A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Phase

III

Principal Investigator

Shenoy, Shalini

Disease Site

Myeloid and Monocytic Leukemia

Learn more about this study at: clinicaltrials.gov